BJMO - 2020, issue Special, october 2020
dr. Siska van Bruwaene , Prof, dr. Karolien Goffin
In recent years, PSMA PET/CT imaging has emerged as one of the hottest topics in prostate cancer. In this respect, results of the proPSMA trial that were published earlier this year have the potential to be a real gamechanger in the primary staging of prostate cancer. Nowadays, CT and bone scans are the preferred imaging tools in primary staging, but the results of this trial now indicate that PSMA PET/CT can potentially replace this standard of care. However, many questions remain to be answered: can we forego on CT and bone scan and routinely opt for a one-stop-shop with PSMA PET/CT? Are there specific pitfalls with this technique? What should be the conclusion after a positive/negative result on PSMA PET/CT? In a first session of the 2020 annual BMUC meeting, the results obtained with PSMA PET/CT in the context of primary prostate cancer were critically reviewed with a specific focus on some of these unanswered questions. During this session Dr. Siska van Bruwaene (AZ Groeninge, Kortrijk, Belgium) zoomed in on PSMA PET/CT in the context of lymph node staging after which Prof. Dr. Karolien Goffin (University Hospitals Leuven, Leuven, Belgium) turned the attention to distant disease staging with this imaging technique.
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
